By Chaya Estrin-Lebovic, MPH, CHES, Registry Coordinator; John Wells MBA-HA, PMP, CSSGB, Manager Lung Cancer Registry; Courtney Granville, PhD, MSPH, Chief Scientific Officer Everyone living with lung cancer has unique experiences. Some people discover it unexpectedly—like the young mother [...]
Question: What can I do if I’m having trouble sleeping during lung cancer treatment? Answer: Difficulty sleeping is a common side effect of lung cancer and its treatment. You may have trouble falling asleep, staying asleep, or still feel [...]
Shared decision-making and seeking second opinions are important parts of the healthcare process that can improve patient care. Dr. David Gandara from UC Davis Comprehensive Cancer Center joined GO2’s November 2024 Lung Cancer Living Room® to discuss how he [...]
Matthew Reiss MSE PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer, and Jared Weiss MD, Section Chief of Thoracic and Head & Neck Oncology, Professor of Medicine, University of North Carolina at Chapel Hill It is [...]
Treatment strategies for non-small cell lung cancer (NSCLC) with EGFR mutations have evolved in recent years, including the development and approval of new therapies and combinations of treatments. The best treatment for each person with EGFR NSCLC depends on [...]
Question: I have metastatic lung cancer that is responding well overall to the targeted therapy that I take. However, a few spots in my bones are not shrinking from the treatment. Can radiation therapy help me? (Answered by Dr. [...]
Radiation therapy for lung cancer has seen recent advancements that have improved accuracy and treatment outcomes. Dr. Dan Schiffner from Sutter Health Palo Alto Medical Foundation joined GO2’s September 2024 Lung Cancer Living Room to discuss a radiation oncologist’s role [...]
By Renee Botello MSc, Navigator, Treatment and Trials, GO2 for Lung Cancer and Roy Herbst, MD, PhD Each year, the American Society of Clinical Oncology (ASCO) holds an annual meeting that shares novel breakthroughs and transformative research in oncology. [...]
Author: GO2 for Lung Cancer Treatment and Trials Navigator, Renee Botello MSc Tagrisso (osimertinib) has been the treatment of choice and effective standard of care option for the treatment of EGFR+ non-small cell lung cancer (NSCLC) since its FDA [...]
Author: Rashmi Acharya, MS, Science and Research Specialist, GO2 for Lung Cancer The 2021 World Conference on Lung Cancer (WCLC) had multiple researchers presenting their findings on broad areas of research in early-stage lung cancer. These presentations bring highly [...]